NIH issues details for CNS program

The National Institutes of Health (NIH) released details this month on a new program, called the CounterACT Neurotherapeutics Screening (CNS) Program, in order to accelerate countermeasure development for chemical threats.

This program is open to domestic government laboratories, companies and academic institutions in order to conduct efficacy data to support research proposals submitted to CounterACT or other peer-reviewed grant programs. The notice states that this participation does not replace requirements to collaborate with laboratory facilities that are authorized to work with restricted chemical agents.

As a part of the program, researchers will have access to established screening models involving animal subjects. These would be used to test the efficacy of proposed compounds against organophosphorus chemicals and those that pose a threat to the nervous system.

Those that are accepted by the CNS will not incur costs associated with the supported studies. They note that studies should not overlap with others that are within another CounterACT grant program, but they may be performed together under this program.

Those interested in the program should contact CounterACT Program Project Manager Dave Yeung at For application purposes, suppliers and investigators will need to provide information relating to the candidate's solubility, toxicity, purity and previous efficacy study data if available.

Organizations in this Story

National Institute of Environmental Health Studies (NIH) National Institutes of Health

Want to get notified whenever we write about any of these organizations ?
Next time we write about any of these organizations, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.